Seizure Control As a New Metric in Assessing Efficacy of Tumor Treatment in Patients with Low Grade Glioma

Active, not recruiting

Brief Summary: This study investigates how seizures can vary over time with changes in low grade gliomas and its treatments. This study may help doctors find symptoms or triggers of seizures earlier than normal, and ultimately earlier care or treatment for seizures.

Detailed Description: PRIMARY OBJECTIVE:

I. To evaluate the rate of change of seizure frequency and the status of the tumor at each data collection point.

SECONDARY OBJECTIVES:

I. To obtain sufficient number of patients' data in order to power the analysis to determine whether a change in seizure frequency correlates with tumor control.

II. Evaluate progression free survival and overall survival when compared with seizure control.

OUTLINE:

Patients complete a seizure assessment survey over 5 minutes at each clinic visit.

Recruitment & Eligibility

Inclusion Criteria

Adult patients
Primary brain tumors (separated by World Health Organization [WHO] grade I-IV)
History of seizures secondary to brain tumor
On tumor directed treatment
Magnetic resonance imaging (MRI) within 2 weeks of clinic visit where seizure assessment takes place

Exclusion Criteria

Arm && Interventions

Group	Intervention	Description
Observational (survey)	Survey Administration	Patients complete a seizure assessment survey over 5 minutes at each clinic visit.

Primary Outcome Measures

Name	Time	Method
Rate of change of seizure frequency	Baseline to 2 years	Both average composite scores as well as individual question scores from the seizure survey will be evaluated. Will perform descriptive statistics to characterize the demographic and disease-related features of this population. Will perform regression analyses to the relationship of survey results to clinical and radiographic features. Cox regression analyses for other relevant post-hoc analyses may be performed.
Status of tumor	Up to 2 years	Radiographic information will be derived from brain MRIs performed on each patient at time of diagnosis, and subsequently at times of survey administration. Will perform descriptive statistics to characterize the demographic and disease-related features of this population. Will perform regression analyses to the relationship of survey results to clinical and radiographic features. Cox regression analyses for other relevant post-hoc analyses may be performed.

Secondary Outcome Measures

Name	Time	Method
Patient data collection	Up to 2 years	Will obtain sufficient number of patients' data in order to power the analysis to determine whether a change in seizure frequency correlates with tumor control. Clinical information to be extracted from the medical record includes but not limited to; date of birth, gender, date of diagnosis, clinical symptoms referable to the brain tumor, functional status and age at diagnosis, treatments applied, dates of progression, and date of death. Radiographic information will be derived from brain MRIs performed on each patient at time of diagnosis, and subsequently at times of survey administration. Will perform descriptive statistics to characterize the demographic and disease-related features of this population.
Progression-free survival (PFS)	Up to 2 years	Will evaluate PFS when compared with seizure control.
Overall survival (OS)	Up to 2 years	Will evaluate OS when compared with seizure control.

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial